Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
37 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Graves Diseases - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves Diseases - Pipeline Review, H2 2016, provides an overview of the Graves Diseases (Hormonal Disorders) pipeline landscape. Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones (hyperthyroidism). Symptoms include anxiety, weight loss, change in menstrual cycles, erectile dysfunction, bulging eyes and irregular heartbeat. Risk factors include family history, age, autoimmune disorders, smoking and pregnancy. Treatment includes anti-thyroid medications, beta blockers and surgery. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves Diseases - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Graves Diseases (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Graves Diseases (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Graves Diseases and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2 and 1 respectively. Graves Diseases (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Graves Diseases (Hormonal Disorders). - The pipeline guide reviews pipeline therapeutics for Graves Diseases (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Graves Diseases (Hormonal Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Graves Diseases (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Graves Diseases (Hormonal Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Graves Diseases (Hormonal Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Graves Diseases (Hormonal Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Graves Diseases Overview 6 Therapeutics Development 7 Pipeline Products for Graves Diseases - Overview 7 Graves Diseases - Therapeutics under Development by Companies 8 Graves Diseases - Pipeline Products Glance 9 Clinical Stage Products 9 Early Stage Products 10 Graves Diseases - Products under Development by Companies 11 Graves Diseases - Companies Involved in Therapeutics Development 12 Apitope International NV 12 Nova Therapeutics LLC 13 Novartis AG 14 Omeros Corp 15 Rodos BioTarget GmbH 16 Graves Diseases - Therapeutics Assessment 17 Assessment by Monotherapy Products 17 Assessment by Target 18 Assessment by Mechanism of Action 20 Assessment by Route of Administration 22 Assessment by Molecule Type 24 Drug Profiles 26 ATXGD-59 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 CFZ-533 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 K-170 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 NV-02 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 Protein for Graves Diseases - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Small Molecule to Target GPR174 for Immunology, Neurology and Oncology - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Graves Diseases - Dormant Projects 33 Graves Diseases - Product Development Milestones 34 Featured News & Press Releases 34 Oct 26, 2016: Apitope Announces Enrolment of First Patient in Phase I Trial of ATX-GD-59 for the Treatment of Graves Disease 34 Jun 19, 2014: Apitope Progresses Graves' Disease Treatment 34 Appendix 36 Methodology 36 Coverage 36 Secondary Research 36 Primary Research 36 Expert Panel Validation 36 Contact Us 36 Disclaimer 37
List of Tables
Number of Products under Development for Graves Diseases, H2 2016 7 Number of Products under Development by Companies, H2 2016 8 Comparative Analysis by Clinical Stage Development, H2 2016 9 Products under Development by Companies, H2 2016 11 Graves Diseases - Pipeline by Apitope International NV, H2 2016 12 Graves Diseases - Pipeline by Nova Therapeutics LLC, H2 2016 13 Graves Diseases - Pipeline by Novartis AG, H2 2016 14 Graves Diseases - Pipeline by Omeros Corp, H2 2016 15 Graves Diseases - Pipeline by Rodos BioTarget GmbH, H2 2016 16 Assessment by Monotherapy Products, H2 2016 17 Number of Products by Stage and Target, H2 2016 19 Number of Products by Stage and Mechanism of Action, H2 2016 21 Number of Products by Stage and Route of Administration, H2 2016 23 Number of Products by Stage and Molecule Type, H2 2016 25 Graves Diseases - Dormant Projects, H2 2016 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.